141 results found.

Breast Cancer, or Neoplasm Metastasis Clinical Trial using Standard supportive care (packed RBC transfusion); epoetin alfa + packed RBC transfusion

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Standard supportive care (packed RBC transfusion); epoetin alfa + packed RBC transfusion

Metastatic Breast Cancer Clinical Trial using Cisplatin; Metronomic Cyclophosphamide

Centre Jean Perrin - Recruiting 18 years or older.
- .
Cisplatin; Metronomic Cyclophosphamide

Metastatic Breast Cancer Clinical Trial using Palbociclib; Fulvestrant; Placebo

Pfizer - Recruiting 18 years or older.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex?) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy.
Palbociclib; Fulvestrant; Placebo

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

Japan Breast Cancer Research Group - Recruiting 20 years to 75 years.
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-.
Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

HER2 Positive Metastatic Breast Cancers Clinical Trial using ONT-380; Capecitabine; Trastuzumab

Oncothyreon Inc. - Recruiting 18 years or older.
- A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer.
ONT-380; Capecitabine; Trastuzumab

Solid Cancers Clinical Trial using letrozole; fulvestrant; GDC-0032

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer.
letrozole; fulvestrant; GDC-0032

Breast Cancer Clinical Trial using GDC-0941; placebo; fulvestrant; GDC-0980

Genentech - Recruiting 18 years or older.
- A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy.
GDC-0941; placebo; fulvestrant; GDC-0980

Breast Cancer Clinical Trial using GDC-0941; Placebo; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer.
GDC-0941; Placebo; paclitaxel

Breast Cancer Clinical Trial

Genentech - Recruiting 18 years or older.
- An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study))..

Breast Cancer Clinical Trial using GDC-0032; Docetaxel; Paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
GDC-0032; Docetaxel; Paclitaxel

Metastatic Breast Cancer Clinical Trial using PF-05280014; Paclitaxel; Herceptin®

Pfizer - Recruiting 18 years or older.
- A Phase 3 Randomized, Double-Blind Study Of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-Line Treatment Of Patients With HER2-Positive Metastatic Breast Cancer.
PF-05280014; Paclitaxel; Herceptin®

Metastatic Breast Cancer Clinical Trial using Anakinra plus Standard of Care

Baylor Research Institute - Recruiting 18 years to 80 years.
- Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients.
Anakinra plus Standard of Care

Breast Cancer Clinical Trial using Paclitaxel; BKM120 matching placebo; BKM120

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation..
Paclitaxel; BKM120 matching placebo; BKM120

Advanced Cancer, Metastatic Cancer, Lymphoma, Metastatic Breast C Clinical Trial using LY3023414; Midazolam; Letrozole

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer.
LY3023414; Midazolam; Letrozole

Metastatic GPNMB Over-expressing Triple Negative Breast Cancer Clinical Trial using CDX-011; Capecitabine

Celldex Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study).
CDX-011; Capecitabine

Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Recep Clinical Trial using nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer.
nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Metastatic Breast Cancer Clinical Trial using Mammaglobin-A DNA vaccine

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients With Metastatic Disease.
Mammaglobin-A DNA vaccine

Breast Cancer Clinical Trial using Capecitabine; Exemestane; Everolimus

Novartis - Recruiting 18 years or older.
- Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole..
Capecitabine; Exemestane; Everolimus

Metastatic Breast Cancer Clinical Trial using TDM1; Lapatinib; Abraxane

The Methodist Hospital System - Recruiting 18 years or older.
- Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients.
TDM1; Lapatinib; Abraxane

Breast Cancer Clinical Trial using pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer..
pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Breast Cancer Clinical Trial using taxane; pertuzumab; trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer.
taxane; pertuzumab; trastuzumab [Herceptin]

Breast Cancer Clinical Trial using trastuzumab emtansine

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
trastuzumab emtansine

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Randomized, Multicenter Phase III Study in Patients With HER2-positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab.
trastuzumab [Herceptin]

Breast Cancer Clinical Trial using Kadcyla (trastuzumab emtansine)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-based Treatment..
Kadcyla (trastuzumab emtansine)

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Advanced HER2-positive Breast Cancer or Gastric Cancer Clinical Trial using LJM716; Trastuzumab

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer.
LJM716; Trastuzumab

Metastatic Breast Cancer Clinical Trial using Fulvestrant; Goserelin; Anastrozole

Hospital Affiliated to Military Medical Science, Beijing - Recruiting 18 years to 60 years.
- The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer.
Fulvestrant; Goserelin; Anastrozole

Metastatic Breast Cancer Clinical Trial using Docetaxel

Centro Universitario contra el Cáncer - Recruiting 21 years to 85 years.
- Docetaxel in Patients With Metastatic Breast Cancer Who Have Been Heavily Pretreated, Including Prior Treatment With Paclitaxel or Docetaxel..
Docetaxel

Hormone Receptor Positive Breast Cancer Clinical Trial using faslodex 500mg; arimidex 1mg; faslodex dummy; arimidex dummy

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy..
faslodex 500mg; arimidex 1mg; faslodex dummy; arimidex dummy

FGFR Inhibition, Pharmacokinetics, Biomarkers, or ER+ Breast Canc Clinical Trial using AZD4547; Exemestane; Placebo; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW).
AZD4547; Exemestane; Placebo; Fulvestrant

Breast Cancer Clinical Trial using Lapatinib; Herceptin

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer.
Lapatinib; Herceptin

Advanced Metastatic Breast Cancer Clinical Trial using AZD2014; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
AZD2014; Fulvestrant

Breast Cancer, Breast Neoplasm, Breast Tumor, or Cancer of the Br Clinical Trial using Proton Radiotherapy

Proton Collaborative Group - Recruiting 18 years or older.
- Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Women With Stage III,Loco-Regional, Non-Metastatic Breast Cancer.
Proton Radiotherapy

Metastatic Cancers Other Than Melanoma That Express ESO Antigen, Clinical Trial using Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes.
Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

Local Advanced or Metastatic Postmenopausal Breast Cancer Clinical Trial

AstraZeneca - Recruiting N/A or older.
- LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer.

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Reolysin

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer.
Paclitaxel; Reolysin

Breast Neoplasms, or Breast Cancer Clinical Trial using Taxane; Taxotere; Abraxane; Ixabepilone

The Methodist Hospital System - Recruiting 18 years or older.
- Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy..
Taxane; Taxotere; Abraxane; Ixabepilone

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673; Physician's-Choice

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease.
BMN 673; Physician's-Choice

Metastatic Breast Cancer With Intracranial Metastases Clinical Trial using cabazitaxel; lapatinib

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases.
cabazitaxel; lapatinib

Breast Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study).

Breast Cancer Clinical Trial using Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer.
Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Metastatic Breast Cancer Clinical Trial using eribulin mesylate; Trastuzumab

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy.
eribulin mesylate; Trastuzumab

Neoplasms, Breast Clinical Trial using lapatinib; trastuzumab; Aromatase inhibitor

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies.
lapatinib; trastuzumab; Aromatase inhibitor

Breast Cancer Metastatic Clinical Trial using PF-03084014; Docetaxel

Pfizer - Recruiting 18 years or older.
- Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer.
PF-03084014; Docetaxel

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinet Clinical Trial using AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies..
AZD5363

Breast Neoplasms Clinical Trial using Neratinib

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer.
Neratinib

Metastatic Castration-resistant Prostate Cancer, or Metastatic Br Clinical Trial using Abiraterone acetate

Janssen Research & Development, LLC - Recruiting N/A or older.
- A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Abiraterone acetate

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation.
BMN 673

Male Breast Cancer, Recurrent Breast Cancer, or Stage IV Breast C Clinical Trial using eribulin mesylate; laboratory biomarker analysis

University of Washington - Recruiting 18 years or older.
- Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC).
eribulin mesylate; laboratory biomarker analysis

Breast Neoplasm, or Metastasis Clinical Trial using Eribulina

Medica Scientia Innovation Research - Recruiting 18 years or older.
- A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes.
Eribulina

Metastatic Breast Cancer Clinical Trial using fresolimumab (GC1008); Radiation Therapy

New York University School of Medicine - Recruiting 18 years or older.
- Fresolimumab and Radiotherapy in Metastatic Breast Cancer.
fresolimumab (GC1008); Radiation Therapy

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Breast Cancer, HER-2 Positive Breast Cancer, or Triple Negative B Clinical Trial using ganetespib

Synta Pharmaceuticals Corp. - Recruiting 18 years or older.
- An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer.
ganetespib

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Clinical Trial using cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Male Breast Cancer, Recurrent Breast Cancer, or Stage IV Breast C Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; questionnaire administration

City of Hope Medical Center - Recruiting 65 years or older.
- Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Metastatic Breast Cancer.
paclitaxel albumin-stabilized nanoparticle formulation; questionnaire administration

Breast Cancer Clinical Trial using palliative surgery; therapeutic conventional surgery; palliative radiation therapy; radiation therapy

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer.
palliative surgery; therapeutic conventional surgery; palliative radiation therapy; radiation therapy

Breast Cancer Clinical Trial using TPI 287; Dexamethasone; Benadryl; Ranitidine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain.
TPI 287; Dexamethasone; Benadryl; Ranitidine

HER2-positive Metastatic Breast Cancer Clinical Trial using Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1

Swiss Group for Clinical Cancer Research - Recruiting 18 years or older.
- A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer.
Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1

Breast Cancer Clinical Trial using BKM120

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer.
BKM120

Recurrent Breast Cancer, or Metastatic Breast Cancer Clinical Trial using Ruxolitinib; Paclitaxel

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer.
Ruxolitinib; Paclitaxel

Breast Neoplasms Clinical Trial using Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting.
Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Advanced or Metastatic Breast Cancer,, or ER+ve Advanced or Metas Clinical Trial using AZD5363 when combined with weekly paclitaxel.; AZD5363when combined with weekly paclitaxel.; A placebo in combination with weekly paclitaxel.

AstraZeneca - Recruiting 18 years or older.
- A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status..
AZD5363 when combined with weekly paclitaxel.; AZD5363when combined with weekly paclitaxel.; A placebo in combination with weekly paclitaxel.

Neoplasms Clinical Trial using bevacizumab plus docetaxel

Tampere University Hospital - Recruiting 18 years or older.
- Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer.
bevacizumab plus docetaxel

Breast Cancer Clinical Trial using MAB HER 2 (HERCEPTIN)

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity.
MAB HER 2 (HERCEPTIN)

Breast Neoplasm Clinical Trial

Medica Scientia Innovation Research - Recruiting 18 years or older.
- Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib.

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; paclitaxel; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer.
trastuzumab [Herceptin]; paclitaxel; docetaxel

Breast Cancer Clinical Trial using Pegylated liposomal doxorubicin

University of Arizona - Recruiting 18 years or older.
- A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin.
Pegylated liposomal doxorubicin

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Colorectal Cancer Clinical Trial using Cetuximab; Neratinib

National Surgical Adjuvant Breast and Bowel Project (NSABP) - Recruiting 18 years or older.
- A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With 'Quadruple Wild-Type' (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab.
Cetuximab; Neratinib

Advanced or Metastatic Solid Tumors, or Advanced or Metastatic Br Clinical Trial using Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

University of Utah - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.
Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

Primary Breast Cancer, or Recurrent/Metastatic Breast Cancer Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Breast Cancer Proteomics and Molecular Heterogeneity.

Her2 Positive Metastatic Breast Cancer Clinical Trial using non-pegylated liposomal doxorubicon (MyocetT); Lapatinib (TyverbT)

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes.
non-pegylated liposomal doxorubicon (MyocetT); Lapatinib (TyverbT)

Breast Cancer Clinical Trial using Eribulin; Carboplatin

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer.
Eribulin; Carboplatin

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

HER2-positive Breast Cancer, Recurrent Breast Cancer, or Stage IV Clinical Trial using pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 19 years or older.
- Phase II Prospective Open Label Single Arm Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Metastatic Breast Cancer.
pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Bre Clinical Trial using entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed.
entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

Advanced, Metastatic Breast Cancer Clinical Trial using LEE011; Letrozole; Letrozole Placebo

Novartis - Recruiting N/A or older.
- A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease.
LEE011; Letrozole; Letrozole Placebo

HER2-negative Und Hormone-receptor Positive Metastatic Breast Can Clinical Trial using Everolimus in combination with standard endocrine therapy

University of Ulm - Recruiting 18 years or older.
- DETECT IV - A Multicenter Single Arm Phase II Study to Investigate the Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor Positive, HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells..
Everolimus in combination with standard endocrine therapy

HER2-positive Metastatic Breast Cancer Clinical Trial using Trastuzumab; Paclitaxel

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptinr (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients.
Trastuzumab; Paclitaxel

Pain Clinical Trial using Doxycycline

Ottawa Hospital Research Institute - Recruiting 19 years or older.
- A Phase 2 Trial Exploring the Clinical and Correlative Effects of Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer.
Doxycycline

Breast Cancer Clinical Trial using allogeneic GM-CSF-secreting breast cancer vaccine; trastuzumab; cyclophosphamide

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu.
allogeneic GM-CSF-secreting breast cancer vaccine; trastuzumab; cyclophosphamide

Breast Cancer, Gastric Cancer Clinical Trial using trastuzumab emtansine; capecitabine

Hoffmann-La Roche - Recruiting 18 years or older.
- PHASE I FOLLOWED BY PHASE II STUDY OF THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND CAPECITABINE IN HER2-POSITIVE METASTATIC BREAST CANCER AND HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS.
trastuzumab emtansine; capecitabine

Metastatic Breast Cancer, or Carcinomatous Meningitis Clinical Trial using Trastuzumab

Institut Curie - Recruiting 18 years or older.
- Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.
Trastuzumab

Metastatic Breast Cancer Clinical Trial using Fulvestrant; Everolimus; Placebo (for Everolimus)

PrECOG, LLC. - Recruiting 18 years or older.
- Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy.
Fulvestrant; Everolimus; Placebo (for Everolimus)

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

University of Washington - Recruiting 18 years or older.
- Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

Metastatic Breast Cancer Clinical Trial using Veliparib; Temozolomide; Carboplatin; Paclitaxel; Placebo

AbbVie - Recruiting 18 years or older.
- A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer.
Veliparib; Temozolomide; Carboplatin; Paclitaxel; Placebo

Hodgkin Lymphoma, or Metastatic Breast Cancer Clinical Trial

Rennes University Hospital - Recruiting 18 years to 75 years.
- BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology.

Metastatic Breast Cancer Clinical Trial using vinorelbine; carboplatin; trastuzumab

National Cancer Institute, Naples - Recruiting 18 years to 75 years.
- Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study.
vinorelbine; carboplatin; trastuzumab

Breast Cancer Clinical Trial using BKM120 Matching placebo; Fulvestrant; BKM120

Novartis - Recruiting 18 years or older.
- A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
BKM120 Matching placebo; Fulvestrant; BKM120

Breast Cancer Clinical Trial using BRN01; Placebo

Centre Leon Berard - Recruiting 18 years to 90 years.
- Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy.
BRN01; Placebo

Metastatic Breast Cancer, Colorectal Cancer, or Prostate Cancer Clinical Trial using Foxy-5

WntResearch AB - Recruiting 18 years or older.
- Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colorectal or Prostate Cancer.
Foxy-5

Breast Neoplasms, HER2 Protein, Human, or Geriatric Health Servic Clinical Trial using Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

City of Hope Medical Center - Recruiting 60 years or older.
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer.
Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

Metastatic Breast Cancer Clinical Trial using Docetaxel; Placebo; Indoximod

NewLink Genetics Corporation - Recruiting 18 years or older.
- A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination With 1-methyl-D-tryptophan (Indoximod) in Metastatic Breast Cancer.
Docetaxel; Placebo; Indoximod

Metastatic Breast Cancer, Lung Metastases, or Liver Metastases Clinical Trial using anti-OX40 antibody

Providence Health & Services - Recruiting 18 years or older.
- Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy..
anti-OX40 antibody

Pre-treated Postmenopausal Patients With ER/PgR-negative/AR-posit Clinical Trial using DHEA (Dehydroepiandrosterone)

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori - Recruiting 18 years or older.
- A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT).
DHEA (Dehydroepiandrosterone)

Breast Cancer Clinical Trial using Questionnaire; Interview

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Spousal Relationships and Pain in Metastatic Breast Cancer.
Questionnaire; Interview

Breast Cancer Clinical Trial using Dasatinib and Paclitaxel

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 90 years.
- A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma.
Dasatinib and Paclitaxel

Breast Cancer Clinical Trial using Trastuzumab (Herceptin); Trastuzumab (Herceptin) plus Everolimus

Emory University - Recruiting 18 years or older.
- Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer.
Trastuzumab (Herceptin); Trastuzumab (Herceptin) plus Everolimus

Metastatic Breast Cancer Clinical Trial using 89Zr-trastuzumab injection

University Medical Centre Groningen - Recruiting 18 years or older.
- HER2-PET as a Diagnostic Tool in Breast Cancer Patients With a Clinical Dilemma.
89Zr-trastuzumab injection

Breast Cancer Clinical Trial using Dovitinib; Aromatase Inhibitors

Georgetown University - Recruiting 18 years or older.
- A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer.
Dovitinib; Aromatase Inhibitors

Metastatic Beast Cancer Clinical Trial using Exemestane; Cyclophosphamide

New York University School of Medicine - Recruiting 18 years or older.
- Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer.
Exemestane; Cyclophosphamide

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Breast Cancer Clinical Trial using abiraterone acetate; laboratory biomarker analysis; pharmacogenomic studies

Cancer Research UK - Recruiting 18 years or older.
- A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients With Oestrogen (ER) or Androgen Receptor (AR) Positive Advanced or Metastatic Breast Carcinoma.
abiraterone acetate; laboratory biomarker analysis; pharmacogenomic studies

Metastatic Breast Cancer Clinical Trial using Everolimus

German Breast Group - Recruiting 18 years or older.
- A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus.
Everolimus

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, o Clinical Trial using CTLA-4 Antibody; Hypofractionated Radiotherapy

Western Regional Medical Center - Recruiting 18 years or older.
- A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST).
CTLA-4 Antibody; Hypofractionated Radiotherapy

Breast Cancer Clinical Trial using Abiraterone Acetate

UNICANCER - Recruiting 18 years or older.
- A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer.
Abiraterone Acetate

HER-2 Positive Breast Cancer Clinical Trial using T-DM1; 89Zr-trastuzumab

Jules Bordet Institute - Recruiting 18 years or older.
- Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1.
T-DM1; 89Zr-trastuzumab

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-small-ce Clinical Trial using MORAb-066

Morphotek - Recruiting 18 years or older.
- A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies.
MORAb-066

Breast Cancer Clinical Trial using pertuzumab in combination with trastuzumab and paclitaxel

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer.
pertuzumab in combination with trastuzumab and paclitaxel

Metastatic Breast Cancer Clinical Trial using Cisplatin/Capecitabine

Chinese Academy of Medical Sciences - Recruiting 18 years to 70 years.
- Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients.
Cisplatin/Capecitabine

Breast Cancer Clinical Trial using everolimus; abraxane

Rutgers, The State University of New Jersey - Recruiting 18 years or older.
- Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG).
everolimus; abraxane

Metastatic Breast Cancer Clinical Trial using Doxorubicin/Genexol-PM

Gachon University Gil Medical Center - Recruiting 18 years or older.
- A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer.
Doxorubicin/Genexol-PM

Metastatic Breast Cancer HR+, HER2- Clinical Trial using Fulvestrant; BKM120; BKM120 matching placebo

Novartis - Recruiting 18 years or older.
- A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment.
Fulvestrant; BKM120; BKM120 matching placebo

Metastatic Breast Cancer Clinical Trial using Action Group; Standard care

Centre Leon Berard - Recruiting 18 years or older.
- Randomized Controlled Trial Assessing the Impact of Routine 'Oncologist-supportive Care Team' Consultation on the Use of an Additional Line of Chemotherapy in Metastatic Breast Cancer Patients.
Action Group; Standard care

Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, o Clinical Trial using Eribulin in Combination w/ Cyclophosphamide

University of California, San Francisco - Recruiting 18 years to 80 years.
- A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies.
Eribulin in Combination w/ Cyclophosphamide

Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Clinical Trial using assessment of therapy complications

Southwest Oncology Group - Recruiting N/A or older.
- S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment.
assessment of therapy complications

Metastatic Breast Cancer Clinical Trial using TRC105

Tracon Pharmaceuticals Inc. - Recruiting 18 years or older.
- An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer.
TRC105

Metastatic Breast Cancer Clinical Trial using Lapatinib; Metformin

Fondazione Michelangelo - Recruiting 18 years or older.
- Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy.
Lapatinib; Metformin

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clinical Trial using Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30).
Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Post Menopausal, Hormone Receptor Positive Breast Cancer Clinical Trial using TAK700

University of Wisconsin, Madison - Recruiting 18 years or older.
- CO11109: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer.
TAK700

Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-p Clinical Trial using therapeutic estradiol; exemestane; laboratory biomarker analysis; enzyme-linked immunosorbent assay

University of Arizona - Recruiting N/A or older.
- A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance.
therapeutic estradiol; exemestane; laboratory biomarker analysis; enzyme-linked immunosorbent assay

Breast Cancer Clinical Trial using Paclitaxel 80 mg/m2; Nab-paclitaxel 100 mg/m2 days 1, 8 and 15; Nab-paclitaxel 150 mg/m2 days 1, 8 and 15; Nab-paclitaxel 150 mg/m2 days 1 and 15

Asociaci¢n Oncosur - Recruiting 18 years or older.
- Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer..
Paclitaxel 80 mg/m2; Nab-paclitaxel 100 mg/m2 days 1, 8 and 15; Nab-paclitaxel 150 mg/m2 days 1, 8 and 15; Nab-paclitaxel 150 mg/m2 days 1 and 15

Metastatic Breast Cancer Clinical Trial using lapatinib plus oral vinorelbine

National Taiwan University Hospital - Recruiting 20 years or older.
- Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer.
lapatinib plus oral vinorelbine

Metastatic Breast Cancer Starting a Third Line Chemotherapy Clinical Trial using Construction of a prognostic score (non-drug intervention types)

Institut Claudius Regaud - Recruiting 18 years or older.
- Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival.
Construction of a prognostic score (non-drug intervention types)

Metastatic Breast Cancer Clinical Trial using Metformin; Placebo

Ozmosis Research Inc. - Recruiting 18 years to 75 years.
- A Randomized Phase II, Double Blind, Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Receiving First or Second Line Chemotherapy With Anthracycline, Taxane, Platinum or Capecitabine Based Regimens.
Metformin; Placebo

Metastatic Breast Cancer Clinical Trial

iOMEDICO AG - Recruiting 18 years or older.
- Nabucco - Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer.

Breast Cancer Nos Metastatic Recurrent Clinical Trial using NK105; Paclitaxel

Nippon Kayaku Co.,Ltd. - Recruiting 20 years to 74 years.
- A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer.
NK105; Paclitaxel

Breast Neoplasm Clinical Trial using Tesetaxel once every 3 weeks; Tesetaxel once weekly

Genta Incorporated - Recruiting 18 years or older.
- A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer.
Tesetaxel once every 3 weeks; Tesetaxel once weekly

HER2-negative Metastatic Breast Cancer, or HER2-positive Circulat Clinical Trial using standard chemo- or endocrine therapy; standard chemo- or endocrine therapy + Lapatinib

Heinrich-Heine University, Duesseldorf - Recruiting 18 years or older.
- DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells.
standard chemo- or endocrine therapy; standard chemo- or endocrine therapy + Lapatinib

Breast Cancer Clinical Trial using lobaplatin; cisplatin

Harbin Medical University - Recruiting 18 years to 70 years.
- .
lobaplatin; cisplatin

Breast Cancer, or Neoplasm Metastasis Clinical Trial using Non pegylated liposomal doxorubicin, trastuzumab, docetaxel

Catharina Ziekenhuis Eindhoven - Recruiting 18 years or older.
- Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer.
Non pegylated liposomal doxorubicin, trastuzumab, docetaxel

Breast Neoplasms, or Neoplasm Metastasis Clinical Trial

Beijing Cancer Hospital - Recruiting 18 years to 75 years.
- Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy.

Metastatic Breast Cancer Clinical Trial using Icaritin

Chinese Academy of Medical Sciences - Recruiting 18 years to 65 years.
- A Phase I ,Single Center, Open-labeling, Single and Dose-escalating Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Novel ERa36 Modifier Icaritin in Advanced Breast Patients.
Icaritin

Metastatic Breast Cancer Clinical Trial using Cetuximab; Trastuzumab

Medical University of Vienna - Recruiting 18 years or older.
- Phase I Study Investigating the Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer With High and Moderate HER2 Expression.
Cetuximab; Trastuzumab

Breast Cancer, or Metastatic Cancer Clinical Trial using temozolomide; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer.
temozolomide; radiation therapy

Breast Cancer, Cervical Cancer, Endometrial Cancer, or Ovarian Ca Clinical Trial using fluorouracil; pegylated liposomal doxorubicin hydrochloride; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy.
fluorouracil; pegylated liposomal doxorubicin hydrochloride; hyperthermia treatment

Breast Cancer Clinical Trial using docetaxel; vinorelbine; trastuzumab

Danish Breast Cancer Cooperative Group - Recruiting 18 years to 74 years.
- A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer.
docetaxel; vinorelbine; trastuzumab

Metastatic or Locally Advanced Breast Cancer Clinical Trial using trastuzumab

Regione Lombardia - Recruiting 18 years to 70 years.
- TOP Trial. A Randomised Phase III Clinical Trial of Trastuzumab (Herceptin) Optimization in Patients With Locally Advanced and/or Metastatic Breast Cancer Overexpressing HER2 After a First Line Chemotherapy Plus Trastuzumab..
trastuzumab